| 培美曲塞二钠治疗老年中晚期非小细胞肺癌的近期疗效分析 |
| |
| 引用本文： | 王巍炜,王前,陈楠,李高峰. 培美曲塞二钠治疗老年中晚期非小细胞肺癌的近期疗效分析[J]. 中国实用医药, 2008, 3(15): 78-79 |
| |
| 作者姓名： | 王巍炜 王前 陈楠 李高峰 |
| |
| 作者单位： | 650118,昆明,云南省肿瘤医院胸外科 |
| |
| 摘 要： | 目的观察培美曲塞联合顺铂治疗老年中晚期非小细胞肺癌（NSCLC）的临床疗效和毒性反应。方法34例Ⅲ-Ⅳ期NSCLC患者均经病理组织学和（或）细胞学检查确诊。培美曲塞联合顺铂治疗后评价疗效。结果34例患者均可评价,获得完全缓解0CR3例,部分缓解PR12例,有效率为44.1%（15/34）。最主要的毒副反应为白细胞及血小板降低,但均可耐受。结论培美曲塞联合顺铂治疗老年中晚期NSCLC有较好疗效,可明显改善患者生存质量,,毒副反应轻,易于耐受。
|
| 关 键 词： | 非小细胞肺癌 培美曲塞 化疗 老年人 |
Clinical observation of pemetrexed in treating elder advanced non-small cell lung cancer |
| |
| WANG Wei-wei,WANG Qian,CHEN Nan,et al.. Clinical observation of pemetrexed in treating elder advanced non-small cell lung cancer[J]. China Practical Medical, 2008, 3(15): 78-79 |
| |
| Authors: | WANG Wei-wei WANG Qian CHEN Nan et al. |
| |
| Affiliation: | WANG Wei-wei,WANG Qian,CHEN Nan,et al.Tumor Hospital of KunmingYunnan,650118,China |
| |
| Abstract: | Objective To evaluate the clinical effect and toxieity of pemetrexed in treating elder advanced non-small cell lung cancer(NSCLC).Methods 34 patients with advanced NSCLC diagnosed by pathology or cytology were enrolled into the study.The patients received and were evaluated effect after 2~4 cycles.Results Complete remission (CR)was observrd in 3 cases and PR in 12 cases,the total response rate was 44.1%(15/34).1year survival rate was 47.1%(16/34).The main side effects were leucopenia and thrombocytopenia,but they were tolerable.Conclusion The regimen of pemetrexed plus cisplation is effective,safe and well-tolerable in the treatment of elder advanced NSCLC.It significantly prolong the patients,survival time. |
| |
| Keywords: | Non-small cell lung cancer(NSCLC) Pemetrexed Chemotherapy Elder patients |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
